Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation

Table 6 This table depicts pertinent baseline characteristic and selected admitting diagnoses of patients enrolled into the restrictive arm of the TRICC trial [15] and those in the placebo arm of the randomized controlled trial of rHuEPO treatment of critically ill patients [16], the groups from which our main input parameters were derived*.

	Restrictive strategy, TRICC (N = 418)	Placebo, rHuEPO RCT (n = 652)
Age, mean ± SD, years	57.1 ± 18.1	51 ± 19.4
Gender male	64%	63.7%
APACHE II score, mean ± SD	20.9 ± 7.3	19.6 ± 7.99
Proportion post-operative	39%^a	42.5%
Proportion trauma	20%	48.5%
Proportion sepsis/SIRS	6%	7.7%^b
Proportion respiratory disease	28%	25%^c
Proportion cardiovascular disease	18%	5.4%

*TRICC, Transfusion Requirements in Critical Care¹⁵; rHuEPO, recombinant human erythropoietin; RCT, randomized controlled trial; SD, standard deviation; APACHE, Acute Physiology and Chronic Health Evaluation; SIRS, systemic inflammatory response syndrome.
^aThis is the number corresponding to proportion of patients with location before ICU admission being the operating room or the recovery room¹⁵
^bThis was calculated by adding together the proportion of sepsis and SIRS patients¹⁶
^cThis was calculated by adding together the proportion of patients with pneumonia, ARDS and other respiratory diagnoses¹⁶

ISSN: 1472-6963